RaySearch Laboratories AB (publ) announces that The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), in the USA, has placed an order for the treatment planning system RayStation®*. Revenue from the order will be recognized in the fourth quarter, 2022.
The OSUCCC - James is the third largest cancer hospital in the USA and one of only 53 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers in the nation. Further, Ohio State is the first hospital system to bring proton therapy to Columbus and the central Ohio area.
The department of Radiation Oncology will utilize a Varian ProBeam® 360 for proton therapy, and also has several Varian linear accelerators in service.
The OSUCCC – James will use the latest RayStation technologies, such as deep learning segmentation, image deformation, adaptive planning, multi-criteria optimization, and fallback planning, which allows for contingency planning and comparison of modalities to help clinicians select the most appropriate treatment technique.
Johan Löf, founder and CEO, RaySearch, says: “RaySearch is a leader in treatment planning for proton therapy and we are proud that yet another prominent proton clinic has selected RayStation. We look forward to supporting OSUCC – James in their clinical operation.”
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RaySearch software is used by over 800 clinics in more than 40 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.
RayStation®* is a flexible, innovative treatment planning system, chosen by many leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare®*. By harmonizing the treatment planning, the care of cancer patients worldwide is improved.
* Subject to regulatory clearance in some markets.
For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
Henrik Bergentoft, CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00